Clinical Trial Update: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase II safety study evaluating vemurafenib followed by ipilimumab in subjects with V600 BRAF-mutated advanced melanoma completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Yervoy (ipilimumab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-10-19